VOYA Investment Management’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$853K Sell
15,143
-2,320
-13% -$151K ﹤0.01% 1507
2025
Q4
$1.4M Sell
17,463
-30,748
-64% -$2.07M ﹤0.01% 1363
2025
Q3
$2.35M Sell
48,211
-10,393
-18% -$643K ﹤0.01% 1169
2025
Q2
$4.37M Sell
58,604
-148
-0.3% -$9.8K ﹤0.01% 1007
2025
Q1
$3.73M Sell
58,752
-258,200
-81% -$17.6M ﹤0.01% 1057
2024
Q4
$24.7M Buy
316,952
+282,521
+821% +$22.7M 0.03% 473
2024
Q3
$2.77M Sell
34,431
-248,986
-88% -$20.1M ﹤0.01% 1233
2024
Q2
$23.4M Buy
283,417
+253,236
+839% +$22.3M 0.02% 493
2024
Q1
$2.58M Sell
30,181
-36,981
-55% -$2.9M ﹤0.01% 1260
2023
Q4
$5.74M Sell
67,162
-10,157
-13% -$878K 0.01% 950
2023
Q3
$6.93M Sell
77,319
-19,995
-21% -$1.79M 0.01% 847
2023
Q2
$8.29M Buy
97,314
+58,143
+148% +$4.92M 0.01% 798
2023
Q1
$3.24M Buy
39,171
+19,646
+101% +$1.59M ﹤0.01% 1161
2022
Q4
$1.54M Sell
19,525
-339
-2% -$27.2K ﹤0.01% 1440
2022
Q3
$1.47M Sell
19,864
-23,112
-54% -$1.66M ﹤0.01% 1449
2022
Q2
$2.8M Buy
42,976
+23,074
+116% +$1.37M 0.01% 967
2022
Q1
$1.26M Buy
19,902
+274
+1% +$14.9K ﹤0.01% 1336
2021
Q4
$1.04M Sell
19,628
-234,602
-92% -$14.3M ﹤0.01% 1530
2021
Q3
$17.9M Sell
254,230
-420
-0.2% -$26.5K 0.04% 371
2021
Q2
$17M Buy
254,650
+54,819
+27% +$3.88M 0.03% 404
2021
Q1
$22.2M Sell
199,831
-31,523
-14% -$3.9M 0.04% 317
2020
Q4
$27.5M Sell
231,354
-13,030
-5% -$1.4M 0.06% 269
2020
Q3
$21.3M Buy
244,384
+33,498
+16% +$2.93M 0.05% 308
2020
Q2
$18.9M Sell
210,886
-27,132
-11% -$2.74M 0.04% 346
2020
Q1
$23.7M Buy
238,018
+48,754
+26% +$5.29M 0.06% 259
2019
Q4
$21.7M Sell
189,264
-44,659
-19% -$5.4M 0.05% 346
2019
Q3
$29.5M Sell
233,923
-4,431
-2% -$562K 0.06% 280
2019
Q2
$28.7M Buy
238,354
+178,154
+296% +$17.5M 0.06% 295
2019
Q1
$5.27M Sell
60,200
-1,669
-3% -$152K 0.01% 769
2018
Q4
$6.19M Sell
61,869
-2,612
-4% -$274K 0.02% 683
2018
Q3
$7.39M Buy
64,481
+33,190
+106% +$3.44M 0.02% 702
2018
Q2
$2.81M Sell
31,291
-1,982
-6% -$167K 0.01% 966
2018
Q1
$2.43M Hold
33,273
0.01% 989
2017
Q4
$1.93M Hold
33,273
﹤0.01% 1060
2017
Q3
$1.49M Buy
33,273
+9,763
+42% +$406K ﹤0.01% 1181
2017
Q2
$928K Buy
23,510
+3,243
+16% +$133K ﹤0.01% 1442
2017
Q1
$822K Hold
20,267
﹤0.01% 1443
2016
Q4
$815K Sell
20,267
-2,054
-9% -$77.4K ﹤0.01% 1450
2016
Q3
$808 Hold
22,321
﹤0.01% 1444
2016
Q2
$647K Hold
22,321
﹤0.01% 1533
2016
Q1
$781K Hold
22,321
﹤0.01% 1420
2015
Q4
$720K Hold
22,321
﹤0.01% 1467
2015
Q3
$721K Sell
22,321
-479,633
-96% -$18M ﹤0.01% 1472
2015
Q2
$20.8M Sell
501,954
-65,328
-12% -$2.75M 0.05% 338
2015
Q1
$25.5M Sell
567,282
-99,108
-15% -$4.14M 0.06% 310
2014
Q4
$24.9M Sell
666,390
-48,770
-7% -$1.79M 0.06% 312
2014
Q3
$25M Sell
715,160
-6,618
-0.9% -$236K 0.06% 308
2014
Q2
$25.5M Sell
721,778
-14,600
-2% -$488K 0.06% 315
2014
Q1
$24M Sell
736,378
-13,500
-2% -$516K 0.06% 306
2013
Q4
$31.6M Buy
749,878
+6,300
+0.8% +$259K 0.07% 253
2013
Q3
$29.7M Buy
743,578
+50,500
+7% +$2.12M 0.07% 252
2013
Q2
$28.7M Buy
+693,078
New +$28.1M 0.08% 244

Other funds holding HAE

VOYA Investment Management's HAE Position: Q1 2026 in Review

VOYA Investment Management reduced its Haemonetics (HAE) stake by 13% in Q1 2026, selling an estimated $151K and leaving 15,143 shares worth $853K. The position accounts for ﹤0.01% of the portfolio, ranked #1507.

VOYA Investment Management first reported a position in HAE in Q2 2013 and has held it in 52 quarters since. The position peaked at $31.6M in Q4 2013. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • VOYA Investment Management held 15,143 shares of Haemonetics worth $853K as of Q1 2026.
  • VOYA Investment Management sold 2,320 Haemonetics shares in Q1 2026, an estimated $151K.
  • Haemonetics made up ﹤0.01% of VOYA Investment Management's portfolio in Q1 2026, its #1507 holding.
  • VOYA Investment Management first reported a position in Haemonetics in Q2 2013 and has held it in 52 quarters since.
  • VOYA Investment Management's Haemonetics position peaked at $31.6M in Q4 2013.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on VOYA Investment Management's 13F filing for Q1 2026, filed 12 May 2026.